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Edited by Veli-Pekka LehtoAbstract Resistance to 4-hydroxy-tamoxifen (OHT), which ap-
pears in breast cancer cells after long-term antiestrogen treat-
ment, may involve irreversible changes of gene expression. We
previously developed a MCF-7 derived cell line (MVLN), in
which OHT rapidly and irreversibly inactivates the expression
of an estrogen-regulated luciferase transgene (Vit-tk-luciferase).
In chromatin immunoprecipitation experiments, heterochromatin
protein 1 (HP1a) was found to be associated with the Vit-tk-lucif-
erase transgene, only when it was inactivated by OHT treatment.
Chimeras composed of either HP1a or the Krupple-associated
box (KRAB) module of KOX-1 protein (known to repress gene
expression by recruitment of HP1 proteins), fused to the estrogen
receptor (ER)–DNA binding domain (DBD) and the androgen
receptor (AR)–ligand binding domain (LBD) were generated
and appeared as potent transcriptional repressors. In stably
transfected MVLN cells, irreversible inactivation of the lucifer-
ase transgene expression obtained with HP1a–ER(DBD)–
AR(LBD) was partial, whereas inactivation obtained with
KRAB–ER(DBD)–AR(LBD) was comparable to that obtained
with OHT, although with a slower kinetics. Altogether, these
data suggest that HP1a is involved in the silencing eﬀects associ-
ated with long-term OHT treatments.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tamoxifen resistance may be due either to a simple selection
process of cells from an already heterogeneous population (this
could be the case for tumors that are resistant from the outset)
or to a two-stage process ﬁrst implying cell alteration by the
drug followed by selection of the new phenotype, providingAbbreviations: AR, androgen receptor; ChIP, chromatin immunopre-
cipitation; ER, estrogen receptor; ERE, estrogen responsive element;
HP1, heterochromatin protein 1; KRAB, Krupple-associated box;
LBD, ligand binding domain; OHT, hydroxy-tamoxifen
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doi:10.1016/j.febslet.2005.06.060that cell growth is no longer inhibited by the cytostatic eﬀect
of tamoxifen.
In previous works on an MCF-7 derived cell line (MVLN
cells) that expresses a luciferase transgene under the control
of an estrogen response element (ERE) [1,2], we showed that
4-hydroxy-tamoxifen (OHT), the active metabolite of tamoxi-
fen, was able to induce a rapid and irreversible silencing of the
transgene [3]. The time course of this phenomenon (roughly 10
days) was clearly incompatible with a selection process and re-
vealed a new facet of antiestrogen action. We showed that this
eﬀect was not a consequence of an alteration of estrogen recep-
tor (ER) transactivation, since pS2, a natural estrogen induc-
ible gene, remained fully expressed even after 9 months of
OHT treatment. Rather, our data pointed out that the inacti-
vation was associated with a chromatin remodeling [4,5]. Then,
we showed that histone deacetylation alone could not lead to
an irreversible inactivation of the transgene [6].
The potential importance of such a phenomenon is manifest
because it is in between long-term eﬀects of tamoxifen and tran-
scriptional silencing. During the past decade, signiﬁcant work
was done concerning mechanisms involved in reversible as well
as in irreversible gene silencing [7–9]. Similarities were found
between mechanisms used to shut down permanently large
blocks of heterochromatin and those used for euchromatic
genes that are turned oﬀ every cell cycle [10]. Heterochromatin
protein 1 (HP1) which was initially identiﬁed as a non-histone
chromosomal protein associated with heterochromatin in Dro-
sophila melanogaster, was found to play a pivotal role in such
processes [10–13]. Three diﬀerent orthologs of Drosophila
HP1 were found in humans and rodents [14]. It was shown that
methylation of histone H3 lysine 9 creates a binding site for
HP1 proteins, and that this modiﬁcation was implicated either
in the subtle and reversible regulation of the cell cycle cyclin E
gene [15–17] or in the maintenance of permanent heterochro-
matic loci [18,19]. In addition, HP1 proteins have been found
to interact with the Krupple-associated box (KRAB) which is
a highly conserved repression domain in the Krupple-class zinc
ﬁnger family of transcription factors [20,21].
At this stage, no direct link has been found between HP1
based mechanisms and the repressive aspects of nuclear recep-
tors. However, HP1 isoforms were found to directly interact
with several cofactors involved in protein complexes that medi-
ate the action of such receptors. First, TIF1a was found to
interact in vitro with several nuclear receptors [22] and alsoblished by Elsevier B.V. All rights reserved.
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ond cofactor, TIF1b (termed KAP-1 in mammalian cells),
which is a co-repressor for the large family of KRAB repressor
domain-containing zinc ﬁnger proteins, was found in an N-
CoR-1 protein complex [25]. Interestingly, N-CoR-1 is directly
recruited by the OHT-liganded ERa [26] and TIF1b interacts
both in vitro and in vivo with HP1 proteins [27,28].
In the present work, we have investigated the connection be-
tween the expression of HP1 proteins and transcriptional
silencing associated with long-term antiestrogen treatments.
The presence of HP1 protein isoforms in the Vit-tk-luciferase
promoter zone was examined and the targeting of HP1 (di-
rectly or through a KRAB module) was used to irreversibly
shut down the expression of the ERE-containing luciferase
transgene in MVLN derived breast cancer cells.2. Materials and methods
2.1. Materials
Estradiol (E2), doxyxyclin (D-9891) and hexadimethrine bromide
(H-9268) were purchased from Sigma. 4-hydroxytamoxifen (OHT)
and Faslodex (ICI182,780) were from Zeneca. R1881 was from NEN
(France). Luciferin was synthesized by G. Auzou (INSERM, Montpel-
lier, France) according to Bowie [29]. Actin antibody (A2066) was
from Sigma, androgen receptor (AR) antibody (C-19) was from San-
ta-Cruz. For chromatin immunoprecipitation (ChIP) experiments,
antibodies against HP1a, HP1c and dimethyl-histone H3 lysine 9 (Di-
MeH3K9)were from Upstate. Vectors of the Tet-On or RevTet-On
system (pTet-On (K-1621-A), pTet-tTS (6248-1), pRevTRE (6137-1))
were from Clontech. Plasmids pCsigL/Env and pC57/Gag-Pol were a
kind gift of Dr. J.L. Battini (IGMM, Montpellier, France). The
ERE-b-Glob-luciferase reporter plasmid was from Dr. P. Balaguer
(INSERM U540, Montpellier, France). Vectors expressing ERa
(HEGO), HP1a or KOX-1 were, respectively, given by P. Chambon,
R. Losson (IGBMC, Strasbourg, France) and Dr. Thiesen (Institut
fu¨r Immunologie, Rostock, Germany) [30]. A single photon counting
camera ARGUS-100 from Hamamatsu Photonics was used to detect
luciferase activity in whole cell, and a Luminoskan Ascent from Lab-
system for luciferase assay of cell lysates.
2.2. Plasmids construction
The pKRAB–ER–AR plasmid was generated using a succession of
three PCRs (primers are available upon request). The 5 0-primer of
ER–DNA binding domain (DBD) contained a HindIII site and the
5 0-primer of AR included a SpeI site, both sites being located before
the initiator methionine. The 3 0-primer of AR–ligand binding domain
(LBD) contained a SalI and a XbaI site upstream the stop codon. The
ER–DBD and AR–LBD were ﬁrst ampliﬁed independently using their
corresponding primers. Then, 2 ll of each PCR were mixed, denatur-
ated, hybridized, and PCR-ampliﬁed using the 5 0 primer of ER-DBD
and the 3 0 primer of AR-LBD. The resulting fragment (i.e.,
ER(DBD)–AR(LBD)) was cloned in an intermediate vector (digested
with HindIII and NheI) that contained a single BamHI site near the
HindIII site. The KRAB domain of KOX-1 was ampliﬁed and inserted
in the intermediate construct containing ER(DBD)–AR(LBD) di-
gested with BamHI and HindIII. Finally, the KRAB–ER(DBD)–
AR(LBD) part of the intermediate construct was digested with BamHI
and ClaI and inserted in the pRevTRE vector.
The pHP1a–ER–AR plasmid was constructed by PCR ampliﬁcation
of the HP1a coding sequence. The 5 0 primer incorporated a BamHI site
beside the initiator methionine and a Kozak consensus. The 3 0 primer
contained a HindIII site allowing the fusion in frame of HP1a with the
ER(DBD)–AR(LBD) moiety. The ampliﬁed PCR fragment was in-
serted in the BamHI/HindIII sites of the pKRAB–ER–AR construct.
All constructs were veriﬁed by sequencing.
2.3. Cell culture conditions and luciferase assay
MCF-7 derived cells were cultured either in Dulbeccos minimum
essential medium (DMEM) with phenol red supplemented with 5%
foetal calf serum (FCS medium) or in DMEM without phenol red sup-plemented with 3% of a steroid free, dextran-coated charcoal-treated
fetal calf serum (DCC medium) unless otherwise stated. During cell
culture, medium and hormones were replaced every 2 days. HEK
293 (human kidney cells) were cultured in DMEM (4.5 g glucose) in
the presence of 10% FCS. For luciferase expression analysis of stably
transfected cell lines, cells were placed in 12-well plates, lysed with
120 ll of lysis buﬀer. Cell lysate was used for luminescence analysis
(20 ll) and 80 ll for protein determination in a standard Lowry assay.
2.4. Stable cell lines
To generate K-MVLN and H-MVLN stable cell lines, a stable
MVLN-Tet-On cell line was ﬁrst generated by transfecting MVLN
cells (that contains the Vit-tk-luciferase transgene) with both the
pTet-On and the pTet-tTS vectors. Resistant cell clones were selected
in the presence of 1 mg/ml G418. The screening was achieved using
transient transfection of the pTRE2-Luc vector control vector and
stimulation with 2 lg/ml doxycyclin in the presence of 1 nM
ICI182,780 (to inhibit the expression of endogenous luciferase gene of
MVLN cells).
The secondary stable transfection of the MVLN-Tet-On cell line was
achieved by viral infection using the RevTet system. The HEK293
packaging cell line containing the farnd T antigen was transfected in
a 10 cm petri dish by a calcium phosphate procedure with: 5 lg
pCsig/Env, 5 lg pC57/Gag-Pol and either pRevKRAB–ER–AR or
pRevHP1a–ER–AR. Twelve hours later, dishes were rinsed and the
10% FCS medium replaced. Twenty-four hours later, the medium con-
taining retrovirus was removed, aliquoted and frozen at 70 C. The
MVLN-Tet-On cell line was infected in a 24-well plate in the presence
of 100 ll of the medium containing retrovirus, supplemented with 4 lg/
ml hexadimethrine bromide. Infected mass cultures (not clonal) were
selected in the presence of medium containing 250 lg/ml hygromycin.
After selection and before experiments, stable MVLN cells containing
KRAB–ER–AR or HP1a–ER–AR (termed, respectively, K-MVLN
and H-MVLN) were cultured in FCS medium containing 250 lg/ml
hygromycin and 1 mg/ml G418.
For irreversible inactivation experiments, cells were treated with
hormones in DCC medium, for various selected times. At the end of
treatment, cells were rinsed, transferred in 12-well plates and stimu-
lated for 48 h in with 1 nM E2. Luciferase expression was recorded
as described above and expressed per mg of protein.
2.5. Western-blot analysis, immunocytochemistry and FISH analysis
Stimulated cells grown in 10 cm petri dish were arrested by the addi-
tion of 250 ll of boiling lysis buﬀer (125 mM Tris, 4% SDS, 20% glyc-
erol, 200 mM DTT). Equal amounts of total protein were resolved
using 10% or 12% SDS–PAGE. Gel electrophoresis, Western blots
and detection were carried out as previously described [31].
For immunochemistry, transfected cells were incubated on cover-
slips in culture medium for 24 h, ﬁxed in methanol at room tempera-
ture, washed, and blocked with 1% bovine serum albumin in
phosphate-buﬀered saline (PBS) for 10 min at room temperature. Cells
were labeled with the C-19 anti-AR antibody at a dilution of 1:200 for
1 h at room temperature, washed, and then labeled with texas red-con-
jugated anti-rabbit goat IgG diluted at 1:800. After the ﬁnal wash, the
cultures were mounted onto slide.
FISH labeling of MVLN cells was performed as described in [32].
The probe was the entire linearised Vit-tk-luciferase plasmid, and
was detected with an antibody conjugated to FITC.
2.6. Chromatin immunoprecipitation analysis
Cells were crosslinked with 1% formaldehyde at 25 C for 10 min,
then quenched with 250 mM glycine. After two washes with cold
PBS, they were resuspended on ice in buﬀer I (10 mM HEPES, pH
6.5, 0.25% Triton X-100, 2.5 mM EDTA, 0.5 mM EGTA, 0.1 mM
PMSF, 1 mM butyrate, 1· protease inhibitor cocktail) for 10 min, cen-
trifuged and collected on ice in buﬀer II (10 mM HEPES, pH 6.5,
1 mM EDTA, 0.5 mM EGTA, 0.1 mM PMSF, 1 mM butyrate, 1·
protease inhibitor cocktail) for 10 min. Cells were centrifuged and
resuspended in 1 ml of lysis buﬀer (25 mM Tris–HCl, pH 7.5,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5%
deoxycholate). Samples were sonicated three times for 32 s at 60% set-
tings (Bioblock Vibra cell, Model 7205) and centrifuged twice at
14000 rpm at 4 C. Supernatants were collected and diluted (DO280
nm: 0.130) in dilution buﬀer (16.7 mM Tris–HCl, pH 8, 0.01% SDS,
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immunoclearing with protein A–Sepharose (20 ll of 50% slurry in dilu-
tion buﬀer, for 100 ll of diluted supernatant) for 2 h at 4 C. Immuno-
precipitation was performed overnight at 4 C with appropriate
antibodies. Sepharose beads were washed sequentially in RIPA
(50 mM Tris–HCl, pH 8, 149 mM NaCl, 0.1% SDS, 0.5% deoxycho-
late, 1% NP-40), for 10 min. High salt buﬀer (50 mM Tris–HCl, pH
8, 0.5 M NaCl, 0.1% SDS, 1% NP-40), LiCl buﬀer (50 mM Tris–
HCl, pH 8, 0.5% deoxycholate, 1% NP-40), and then washed twice
with TE buﬀer. Washed resin was resuspended in elution buﬀer (2%
SDS, 0.1 M NaHCO3, 0.01 M DTT) and reverse crosslinked at
65 C overnight. After digestion with proteinase K, DNA samples were
extracted with phenol:chloroform, and the DNA precipitated over-
night with 1/10 volume of 3 M NaAc + 1 ll glycogen and 2 volumes
of ethanol at 20 C. Radioactive PCRs contained 5 ll of immunopre-
cipitate or total diluted input. The primer sequences were as follows:
forward CCAGGTCCACTTCGCATATT and reverse GCCTTATG-
CAGTTGCTCTCC.3. Results
3.1. Localization of the Vit-tk-luc transgene in MVLN cells
We have previously engineered and characterized an original
MVLN model cell line (derived from MCF-7 estrogen-respon-
sive cells) in which a sustained antiestrogenic treatment irre-
versibly inactivates the expression of speciﬁc E2-regulated
genes [3–5]. In particular, MVLN cells contain an E2-regulated
transgene (Vit-tk-luciferase) that is rapidly (about 10 days) and
irreversibly inactivated by an OHT treatment whose length is
not compatible with a selection process of the cells [3].
In order to specify the proximity of the Vit-tk-luciferase
transgene with heterochromatin, its chromosomal localization
was achieved using FISH analysis on cells in metaphase. The
transgene appeared integrated at a single site as shown by
the staining of chromosomes in metaphase (Fig. 1). This con-
ﬁrmed a previous analysis of the transgene integration site in
these cells which showed by Southern blot that three complete
copies of the vit-tk-luc gene unit were integrated together in a
single site [5]. Interestingly, the FISH analysis showed that theFig. 1. Localization of the Vit-tk-luciferase transgene in MVLN cells.
MVLN cells were grown in FCS medium, then subjected to a FISH
experiment on metaphasic chromosomes as described in Section 2.transgene appeared in a subtelomeric position which is consis-
tent with a heterochromatic based inactivation mechanism dri-
ven by a telomeric structure change [33]. As HP1proteins play
a pivotal role in such mechanisms, we therefore analyzed their
presence on the transgene during irreversible inactivation.
3.2. Chromatin immunoprecipitation analysis of the
Vit-tk-luciferase transgene
In MVLN cells treated with OHT during 45 days (MVLNi
cells), luciferase expression remained still inducible by a 48 h
stimulation with 1 nM E2. However, the maximum luciferase
activity obtained was about 18 times less than in untreated
MVLN cells (Fig. 2A), showing the irreversible inactivation
of the transgene expression.
In order to precise whether HP1 proteins could be involved
in the silencing of the Vit-tk promoter upon inhibition by OHT
treatment, we set up ChIP analysis in either MVLNi or un-
treated MVLN cells. ChIP assays were performed using anti-
bodies against human HP1 a and c isoforms and primers
positioned inside of the tk promoter and the beginning of lucif-
erase sequence (Fig. 2B). Interestingly, we found that HP1a
was clearly associated with the Vit-tk-luciferase transgene in
MVLNi cells, but not in MVLN cells (Fig. 2C). By contrast,
the HP1c isoform was found to be present on the transgene
in both OHT-treated and untreated cells.
Since methylation of lysine 9 of histone H3 (H3K9) has been
shown to be the main modiﬁcation involved in the recruitment
of HP1 proteins, we then investigated whether an increase in
dimethylated H3K9 residue correlated with the binding of
HP1a on the transgene. When corrected with input values,
the quantiﬁcation of ChIP analysis revealed a 3-fold diﬀerence
between MVLNi and MVLN in the signal obtained after
immunoprecipitation with the antibody against dimethylated
H3K9 (Fig. 2C).Fig. 2. ChIP analysis of the Vit-tk-luciferase transgene promoter.
Comparative ChIP assays using chromatin prepared either from
untreated MVLN cells grown in FCS medium, or MVLN cells treated
for 45 days with 100 nM OHT followed by 20 days in FCS medium
(MVLNi). (A) Luciferase activity of the two cell lines recorded just
before ChIP assays. Cells were grown in DCC medium without phenol
red for 3 days, then treated 24 h with 1 nM ICI182, 780 or 1 nM E2. (B)
Schematic representation indicating the primers location in the Vit-tk-
luciferase transgene. (C) Autoradiogram of the ChIP assays performed
as described in Section 2.
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KRAB–ER–AR repressors in transient transfection
experiments
The above-described results suggested that HP1a may be
involved in the transgene inactivation process. In order to
mimic the OHT irreversible inactivation process, we thus
engineered chimeric proteins containing either the HP1a
coding sequence or a repressive module whose activity relies
on the recruitment of HP1 proteins (Fig. 3A). A ﬁrst chi-
mera corresponded to the entire HP1a protein fused in
frame with the DBD of the human ER, followed by the
LBD of the human AR under the control of a doxycyclin-
inducible promoter. Upon binding of the androgen R1881,
this chimeric protein was expected to bind to the estrogen
response element of the Vit-tk-luciferase transgene. In paral-
lel, the KRAB domain of KOX-1 protein, was fused in a
similar conﬁguration to ER(DBD)–AR(LBD). The KRAB
domain is a highly conserved region found in approximately
one-third of the Kru¨ppel-like zinc ﬁnger proteins [34]. When
tethered to DNA, this domain functions as a repressor
through the recruitment of HP1 proteins [35]. As a negative
control, the ER–DBD alone was fused with the AR–LBD.
The above-described chimeric proteins were termed HP1a–
ER–AR, KRAB–ER–AR and ER–AR, respectively.
We ﬁrst checked, by transient cotransfection of HEK293
cells, that the three chimaeras were expressed to comparableFig. 3. Characterization of HP1a–ER–AR and KRAB–ER–AR chimeric pro
cells were transfected in 24-well plates with 0.4 lg of plasmid coding the select
not with 1 lg/ml doxycyclin for 24 h. Samples were subjected to Western bl
Section 2. (C) HeLa cells grown in FCS medium or MCF-7 cells grown in D
plates with 0.4 lg of plasmid coding the selected chimeric protein, 0.1 lg of
Glob-luciferase reporter. Cells were treated for 24 h with 1 lg/ml doxycyclin
were recorded as described in Section 2. Luciferase expression was normalize
treated with doxycyclin in the absence of R1881 was taken as 100%. T
determinations.levels in a doxycyclin-dependent fashion. As shown in
Fig. 3B, using the C19 antibody raised against the C-terminal
part of AR, we detected the three proteins at the expected
molecular weight. To evaluate the functionality of these chime-
ric proteins, we used transient transfection in ER-positive
MCF-7 cells (from which MVLN cells derive) and in ERa-neg-
ative HeLa cells. In both cell lines, the basal expression of the
reporter gene under the ERE-b-globin promoter was quite
high and values corresponding to cells treated with doxycyclin
in absence of R1881 were ﬁxed as a 100% (Fig. 3C). In the ab-
sence of HP1a or KRAB modules, ER–AR liganded with
10 nM R1881 activated the reporter gene transcription. The
amplitude of this activation was relatively modest because
the strongest activation domain (AF-1) of the AR, located
in the N-terminal part, was absent. However, when HP1a or
the KRAB domain were fused to ER–AR, the activation func-
tion of the latter was counteracted, indicating the inhibitory
nature of these modules.
3.4. Obtention of MVLN stably tranfected cells expressing
HP1a–ER–AR or KRAB–ER–AR
Since HP1a–ER–AR and KRAB–ER–AR chimeric pro-
teins showed a repressive behavior in transiently transfected
HeLa cells, the analysis of their activity was then performed
after stable transfection in MVLN cells. We ﬁrst developed
the MVLN-tet-on clonal cell line (obtained after a stableteins. (A) Schematic representation of chimeric proteins. (B) HEK 293
ed chimeric protein and 0.1 lg of pTet-On and pTet-tTs and treated or
ot experiment was performed using the C-19 antibody as described in
CC medium without phenol red for 3 days, were transfected in 24-well
pTet-On and pTet-tTs, 0.2 lg of pCMVb-Gal and 0.2 lg of pEREb-
± 10 nM of R1881. Luciferase expression and b-galactosidase activity
d using b-galactosidase activity, and the normalized expression of cells
he results are expressed as the mean ± S.D. of three independent
4282 J. Oliva et al. / FEBS Letters 579 (2005) 4278–4286transfection of the pTet-on and pTet-tts plasmids in MVLN
cells). Two stably transfected MVLN-tet-on-derived cell lines
expressing the HP1a–ER–AR and KRAB–ER–AR chimeric
proteins and termed, respectively, H-MVLN and K-MVLN,
were generated using a retroviral expression system (as de-
scribed in Section 2).
As shown in Fig. 4A, the two chimeric proteins were found
to be expressed in the corresponding stably transfected cell
lines. However, in the absence of doxycyclin, the KRAB–
ER–AR chimeric protein was found to be expressed at a
low but detectable level. In the study of irreversible inactiva-
tion, we thus compared the eﬀect obtained by modulating the
level of the agonist R1881 in the presence of doxycyclin, in-
stead of modulating the level of doxycyclin in the presence
of R1881. The expression of both proteins was maintained
at a high level even after long-term treatments (8 days) with
100 nM OHT alone or in combination with 10 nM R1881
(Fig. 4A).
Immunolocalization of the HP1a–ER–AR and KRAB–
ER–AR proteins in stable cell lines was performed in theFig. 4. Localization of HP1a–ER–AR and KRAB–ER–AR chimeric protei
DCC medium alone, or with 1 lg/ml doxycyclin in combination with selected
blot experiments were performed using the C-19 antibody as described in Sect
the presence or absence of 1 lg/ml doxycyclin, and treated or not with 10 nM
(left panel) or KRAB–ER–AR (right panel) chimeric proteins was performeabsence or presence of R1881. HP1a–ER–AR chimeric pro-
tein was found in the nucleus, both in the presence or in
the absence of R1881, suggesting that the nuclear localization
signal of HP1a was functional regardless of the presence of
hormone (Fig. 4B, left panel). By contrast, the KRAB–ER–
AR chimeric protein was localized predominantly in the cyto-
plasm in the absence of ligand and in the nucleus in the
presence of R1881 (10 nM), indicating a functional nuclear
transfer induced by the binding of hormone (Fig. 4B, right
panel). The levels of the two chimeric proteins were higher
(at least 5-fold) than that of the endogenous AR as judged
by Western blot analysis (data not shown). Finally, in the
absence of doxycyclin, only a very weak ﬂuorescence was
observed for both transfectant cells which probably corre-
sponded to a background signal rather to endogenous AR
since no nuclear transfer could be seen after R1881 treatment.
Altogether, the above results indicated that the chimeric pro-
teins produced in these cells after doxycylin induction were
transcriptional repressors that underwent a correct nuclear
localization after R1881 stimulation.ns. (A) K-MVLN or H-MVLN cells were treated for 8 days either in
hormones (100 nM OHT or 100 nM OHT + 10 nM R1881). Western
ion 2. (B) Stably transfected MVLN cells were grown in FCS medium in
of R1881 for 1 h. Immunocytochemical localization of HP1a–ER–AR
d by using the C-19 antibody against AR as described in Section 2.
J. Oliva et al. / FEBS Letters 579 (2005) 4278–4286 42833.5. Irreversible inactivation of the Vit-tk-luc transgene by
HP1a–ER–AR and KRAB–ER–AR
We ﬁrst determined the kinetics of OHT irreversible inacti-
vation of Vit-tk-luc transgene in the MVLN-tet-on clone.
After various periods of OHT treatment followed by a 48 h
stimulation by estradiol, cell luciferase expression was mea-
sured. We found that the kinetics of luciferase inactivation
was roughly the same than that observed in MVLN parent cell
line described in [3] with a t1/2 of approximately 4 days
(Fig. 5A dotted line).
After various periods of R1881 treatment in the presence of
doxycyclin, the extent of inactivation was determined for
MVLN-tet-on parent cell line, the K-MVLN and H-MVLN
clones expressing KRAB–ER–AR and HP1a–ER–AR chime-
ric proteins, respectively (Fig. 5A continuous lines). The extent
of inactivation was much higher for the K-MVLN cell line
than for the H-MVLN cell line, whereas it was modest in the
case of the MVLN-tet-on parent cell line. Inactivation t1/2 in
K-MVLN cells was longer (about 12 days) than that obtained
after OHT treatment of MVLN-tet-on cell line. However, after
21 days, the extent of inactivation in K-MVLN cells was al-
most maximal and comparable to that produced after 9 days
of treatment with OHT, indicating that the KRAB module
was very eﬃcient to produce irreversible inactivation of lucif-
erase expression in these cells. By contrast, the extent of inac-
tivation induced by a 21 day-R1881 treatment of H-MVLN
cells was intermediate to that obtained with MVLN-Tet-on
and K-MVLN cells. Interestingly, the eﬀect of the KRAB
module was reversed by the simultaneous competition of li-
ganded ER (Fig. 5B), as it was the case for the OHT eﬀect [3].
Therefore, irreversible inactivation of the Vit-tk-luciferase
trangene can be triggered by the targeting or local recruitment
of HP1, the latter possibility being more eﬃcient. Altogether,
these results indicate that the presence of HP1 protein can mi-
mic some long-term eﬀects of OHT treatment.Fig. 5. Irreversible inactivation of luciferase activity in H-MVLN and K-M
cells were cultured for various selected times in DCC medium containing 2 lg
treatment time, inactivation factor was expressed as the ratio of normalized
factor was then expressed as a percent of that obtained at day 0 of treatment.D
medium containing 2 lg/ml doxycyclin and 100 nM OHT or none (+ethanol
treated for 10 days in the presence of 1 lg/ml doxycyclin in DCC medium eit
of treatments described in A and B, cells were stimulated 48 h with E2 and pr
value of three determinations ± S.D.4. Discussion
Long-term tamoxifen therapy is generally followed by the
appearance of the resistance phenomenon [36]. Although the
selection/mutation process may be involved in resistance mech-
anisms, one cannot exclude a direct eﬀect of the drug on cancer
cells. Using the MVLN model cell line, we demonstrated that
such eﬀects (rapid and irreversible inactivation of the Vit-tk-
luc transgene or slower inactivation of the progesterone recep-
tor natural gene) could occur beside any selection process [4,5].
We then theorized that such inactivation eﬀects might occur
for natural genes involved in growth control and then partici-
pate in the emergence of resistant tumor cells.
In the MVLN model system that we developed, the Vit-tk-
luc transgene was irreversibly inactivated after about 10–20
days of OHT treatment [3–5]. Some other stable cell lines bear-
ing an ERE-b Glob-Luciferase transgene did not show a sim-
ilar transgene inactivation (data not shown), indicating that
this eﬀect could be dependent on the position of the transgene.
The MVLN cellular model of irreversible inactivation is very
attractive because, ﬁrst, most silencing models studied to date
come from Drosophila or Yeast but not mammals, and sec-
ondly, this gene switch is initiated by a single hormonal
change. Usually, the eﬀect of heterochromatin on gene silenc-
ing results from the juxtaposition of euchromatic genes to con-
stitutive heterochromatin, a phenomenon known as position
eﬀect variegation [37]. In Drosophila, the suppressor of varie-
gation HP1 is a protein associated with centromeric hetero-
chromatin but also with telomeres and some euchromatic
sites [38], and has proven to play a pivotal role in gene
silencing.
In addition to our previous studies concerning this inactiva-
tion process, we showed here, using FISH experiments, that
the transgene was located in a subtelomeric position, suggest-
ing that HP1 function is compatible with its potential role inVLN cells. (A) Continuous lines. MVLN-tet-on, H-MVLN, K-MVLN
/ml doxycyclin and 10 nM R1881 or none (+ethanol). At each selected
luciferase activity of +hormone versus  hormone treated cells. This
otted lines. MVLN-tet-on cells were cultured for various times in DCC
), and results were expressed in the same way. (B) K-MVLN cells were
her with Ethanol alone (DCC) or 10 nM R1881 ± 1 nM E2. At the end
ocessed as described in Section 2. All results are expressed as the mean
4284 J. Oliva et al. / FEBS Letters 579 (2005) 4278–4286this phenomenon. Recent studies showed indeed that HP1
binding on H3K9 residues modiﬁed by suv39h1/h2 histone
methyltransferases was required for heterochromatin mainte-
nance but also for capping and silencing function of telomeres
[39–41]. On the other hand, it was shown that HP1 proteins
could be associated with long-term and stable euchromatin
or heterochromatin remodeling [35,42,43]. We thus decided
to study the impact of such proteins on long-term eﬀects of
antiestrogen treatments.
ChIP analysis showed that HP1a was predominantly associ-
ated with the inactivated Vit-tk-luciferase transgene, whereas
HP1c was associated with both inactivated and activated
transgene. In another study using a similar approach, these
two HP1 isoforms were found to be involved in euchromatic
transgene silencing with their respective predominance varying
along the gene [35]. However, the respective role of the three
HP1 isoforms is far from being clearly established, and some
discrepancies exist between studies. When expressed in Dro-
sophila, the a and c isoforms of human HP1, but not b, are
able to enhance heterochromatic silencing [44]. By contrast,
when overexpressed in mouse, the b isoform is able to enhance
heterochromatic silencing [45] revealing the functional com-
plexity of these isoforms.
The only faint diﬀerence between MVLN and MVLNi con-
cerning the H3K9 residue dimethylation, suggests either, that
it may not be accessible to antibodies, being perhaps masked
by surrounding crosslinked protein complexes, or that H3K9
residues may be located outside of the transgene. It is also pos-
sible that trimethylation, instead of H3K9 residue dimethyla-
tion is involved in the inactivation of the transgene or that
other histone amino-acids are modiﬁed during the silencing
process.
Based on HP1a ChIP experiments, we hypothesized that it
was possible to mimic the silencing eﬀect of OHT on Vit-tk-
luciferase transgene by targeting chimeric proteins containing
either HP1a itself, or a repressor module (the KRAB domain
of KOX-1) known to act through the binding of HP1. These
proteins were targeted to EREs through the ER-DBD fused
in frame with the LBD of AR and showed an intrinsic repres-
sive eﬀect that completely counteracted the activation induced
by the AR-LBD (Fig. 3C). Of interest, irreversible inactivation
of the Vit-tk-luciferase trangene was obtained by direct or indi-
rect targeting of HP1 thus mimicking some long-term eﬀects of
OHT treatment.
We previously used a similar strategy to target the functional
HDAC1 enzyme fused to the glucocorticoid receptor LBD [6].
This HDAC1 targeting was however not suﬃcient by itself to
inactivate the transgene, but only increased the speed of the
OHT induced phenomenon. Interestingly, this ﬁrst study indi-
cated that the ERE occupancy by a protein diﬀerent from ER
was not suﬃcient to induce the inactivation process of the
transgene. In the present study, we observed that the expres-
sion of HP1a-ER-AR and its activation by R1881 resulted in
a partial protective eﬀect against OHT induced silencing (data
not shown). This suggested that binding of HP1a–ER–AR to
the ERE might interfere with a more potent silencing complex
recruited in the presence of OHT.
A few constructs using a similar strategy with KRAB or
HP1 modules were already engineered by others, demonstrat-
ing their usefulness. One of them used the KRAB domain or
HDAC1 fused with wild type or mutated AR [46], others used
KRAB domain fused with diﬀerent mutants of ERa, [47–49],or fused to ER(DBD)–PR(LBD) [49]. However, HP1a has
been usually fused by its N-terminal side in chimeric constructs
described in the literature [42,43], whereas the KRAB domain
was fused by both sides. In our constructs, when AR LBD was
fused by its C-terminal part, the chimeric protein lost its inhib-
itory eﬀect, probably due to an impairment of dimerization
(data not shown). One cannot exclude that the weaker eﬀect
of the construct containing HP1a compared to the KRAB do-
main (Figs. 3C and 5A), resulted from the choice of the side
used to make the fusion.
It was already established that the targeting of the KRAB
domain of KOX-1 operates through the recruitment of
KAP-1 and HP1 proteins [35], reinforcing the role of HP1
based mechanisms in long-term silencing processes. KAP-1
coordinates multiple events like: histone deacetylation via the
recruitment of NuRD complex [50], histone lysine 9 methyla-
tion by SETDB1 histone methyltransferase [51], and the
recruitment of HP1 [35]. It is thus possible that a complete
and orchestrated pathway of chromatin modiﬁcations is essen-
tial to get the maximum eﬃciency of inactivation process. The
fact that KAP-1 acts as a platform could explain why the tar-
geting of only one component (HP1a, HDAC1) alone is less
eﬃcient than the targeting of the KRAB domain, itself less eﬃ-
cient than the entire complex recruited by OHT.
As ERs regulate a huge number of target genes [52] through
direct binding to the corresponding promoter regions or
through indirect recruitment via protein–protein interaction
with transcription factors such as AP1 or Sp1, it is conceivable
that long-term OHT treatment could promote the irreversible
inactivation of several other genes involved in cell proliferation
through the recruitment of N-COR-1, KAP-1 and HP1
proteins.
In conclusion, these data constitute to our knowledge, the
ﬁrst report dealing with the potential relationship between
antiestrogen silencing and HP1 proteins. Additional work will
be necessary to precise the exact role of HP1 proteins in such
silencing processes, and to elucidate if HP1 proteins could par-
ticipate in the regulation of natural estrogen-regulated genes
by nuclear receptors.
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